Familial B-cell Lymphoproliferative Disorders
NCT05718986 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2024-05-08
Summary
This study investigates families with at least two cases of B-cell lymphoproliferative disorders (LPD), and evaluates the prevalence of LPD in families, the relationship between medical history, genetic factors, and the risk of familial LPD, and various clinical outcomes for these families in a multiethnic population of Jews and Arabs in Israel.
Conditions
- Lymphoproliferative Disorders
- Premalignant
- Monoclonal B-Cell Lymphocytosis
- Chronic Lymphocytic Leukemia
Interventions
- OTHER
-
No intervention
No intervention
Sponsors & Collaborators
-
Bnai Zion Medical Center
collaborator OTHER_GOV -
University of Haifa
lead OTHER
Principal Investigators
-
Geffen Kleinstern, PhD · University of Haifa
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-06-30
- Primary Completion
- 2028-12-31
- Completion
- 2040-12-31
More Related Trials
-
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
NCT05865301 ·Status: RECRUITING
-
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
NCT02900976 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
NCT01718691 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Responses in Patients With B Cell Malignancies
NCT05170399 ·Status: RECRUITING ·Phase: PHASE4
-
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
NCT01186978 ·Status: COMPLETED ·Phase: NA
-
A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
NCT00983619 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
NCT01234766 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02957019 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
B-Cell Hematologic Malignancy Vaccination Registry
NCT02298816 ·Status: WITHDRAWN
-
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
NCT00176475 ·Status: TERMINATED ·Phase: PHASE1
-
High-dose Methylprednisolone and Rituximab in High Risk B-CLL
NCT00558181 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
NCT05459571 ·Status: COMPLETED ·Phase: PHASE2
-
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
NCT03399513 ·Status: COMPLETED ·Phase: PHASE2
-
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
NCT01447056 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
NCT07029217 ·Status: RECRUITING ·Phase: PHASE3
-
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
NCT00133991 ·Status: COMPLETED ·Phase: PHASE2
-
Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies
NCT02128945 ·Status: COMPLETED ·Phase: PHASE1
-
Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel
NCT05199961 ·Status: TERMINATED ·Phase: NA
-
The Study of ICP-248 in Patients With Mature B-cell Malignancies
NCT05728658 ·Status: RECRUITING ·Phase: PHASE1
-
ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma
NCT00169130 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
NCT00324779 ·Status: COMPLETED ·Phase: PHASE2
-
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
NCT00586391 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02077166 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT01118845 ·Status: COMPLETED ·Phase: PHASE2
-
Low Grade Lymphoma
NCT01698866 ·Status: UNKNOWN ·Phase: PHASE4